ONCT - Oncternal presents TK216 interim data from early stage study in Ewing sarcoma

Oncternal Therapeutics ([[ONCT]] -4.1%) has announced the presentation of interim clinical data from its ongoing Phase 1 trial for TK216, in patients with relapsed or refractory Ewing sarcoma, tumor that forms in bone or soft tissue. Data were presented at European Society for Medical Oncology congress.This study is evaluating safety, tolerability, pharmacokinetics, and tumor response of TK216. Patients entering the trial had previously been treated with a median of three, and as many as eleven prior lines of systemic therapy.TK216 has been generally well tolerated in this trial, with common side effects including myelosuppression (bone marrow suppression), fatigue, nausea and alopecia. Dose limiting toxicities consisted of transient and manageable myelosuppression, primarily neutropenia.Presentation included interim data for 15 evaluable patients treated as of the August 13, 2020 cut-off date. Two of the 15 patients achieved complete responses ((CR)), including one surgical CR. Five patients had stable disease, for a disease control rate of 47%.Enrollment in expansion

For further details see:

Oncternal presents TK216 interim data from early stage study in Ewing sarcoma